
    
      Scheme:

      Eligible stage III and IVA/B NPC patients will first be stratified by institution, then
      randomized to 2 arms at 1:1 ratio.

      - Arm Cisplatin:

      Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3
      weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT

      - Arm nimotuzumab:

      Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3
      weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT
    
  